Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M

PUMA BIOTECHNOLOGY, INC.

2025-Q2 EPS reported $0.18 revenue$98,443,000

GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.
Net product revenue $49.2M (+11% YoY); total revenue $52.4M (+11% YoY).
Q3 2025 guidance: net product revenue $46–48M, total revenue $48–51M, net income $2–4M.
Full-year 2025 revenue outlook reaffirmed at $212–222M; gross-to-net adjustment raised to 21.5–22.0%.
Cash & equivalents $96M; key milestones: alisertib interim data in Q4 2025 for two Phase II trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.